SG11202002195YA - Potentiating the effect of atp release - Google Patents

Potentiating the effect of atp release

Info

Publication number
SG11202002195YA
SG11202002195YA SG11202002195YA SG11202002195YA SG11202002195YA SG 11202002195Y A SG11202002195Y A SG 11202002195YA SG 11202002195Y A SG11202002195Y A SG 11202002195YA SG 11202002195Y A SG11202002195Y A SG 11202002195YA SG 11202002195Y A SG11202002195Y A SG 11202002195YA
Authority
SG
Singapore
Prior art keywords
potentiating
effect
atp release
atp
release
Prior art date
Application number
SG11202002195YA
Other languages
English (en)
Inventor
Stéphanie Chanteux
Nicolas Gourdin
Carine Paturel
Ivan Perrot
Benjamin Rossi
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of SG11202002195YA publication Critical patent/SG11202002195YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202002195YA 2017-11-15 2018-11-15 Potentiating the effect of atp release SG11202002195YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762586224P 2017-11-15 2017-11-15
US201862686149P 2018-06-18 2018-06-18
US201862733175P 2018-09-19 2018-09-19
PCT/EP2018/081364 WO2019096900A1 (en) 2017-11-15 2018-11-15 Potentiating the effect of atp release

Publications (1)

Publication Number Publication Date
SG11202002195YA true SG11202002195YA (en) 2020-04-29

Family

ID=64332078

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002195YA SG11202002195YA (en) 2017-11-15 2018-11-15 Potentiating the effect of atp release

Country Status (11)

Country Link
US (1) US20190218304A1 (enrdf_load_stackoverflow)
EP (1) EP3710052A1 (enrdf_load_stackoverflow)
JP (1) JP7383609B2 (enrdf_load_stackoverflow)
KR (1) KR102781619B1 (enrdf_load_stackoverflow)
CN (1) CN111372606B (enrdf_load_stackoverflow)
AU (1) AU2018368541B2 (enrdf_load_stackoverflow)
BR (1) BR112020009655A8 (enrdf_load_stackoverflow)
CA (1) CA3075371A1 (enrdf_load_stackoverflow)
IL (1) IL273440A (enrdf_load_stackoverflow)
SG (1) SG11202002195YA (enrdf_load_stackoverflow)
WO (1) WO2019096900A1 (enrdf_load_stackoverflow)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6018361B2 (ja) 2008-01-31 2016-11-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
AU2018235092B2 (en) 2017-03-16 2024-09-19 Innate Pharma Compositions and methods for treating cancer
EP3622092A4 (en) * 2017-05-11 2021-06-23 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
WO2019027935A1 (en) 2017-07-31 2019-02-07 Tizona Therapeutics ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES
KR102710877B1 (ko) * 2017-10-06 2024-09-26 이나뜨 파르마 에스.에이. Cd39/cd73 축을 통한 t 세포 활성의 복원
JP7368453B2 (ja) 2018-05-03 2023-10-24 シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
CA3099893A1 (en) 2018-06-18 2019-12-26 Innate Pharma Compositions and methods for treating cancer
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
WO2021088838A1 (zh) * 2019-11-05 2021-05-14 北京加科思新药研发有限公司 对cd39具有特异性的结合分子及其用途
US11450389B2 (en) 2020-07-17 2022-09-20 Samsung Electronics Co., Ltd. Non-volatile memory device and an operation method thereof
CN115975030B (zh) 2021-09-30 2023-09-26 杭州邦顺制药有限公司 抗cd39抗体-药物偶联物及其用途
US11970543B2 (en) 2022-03-03 2024-04-30 Arcus Biosciences, Inc. Anti-CD39 antibodies and use thereof
AU2023227505A1 (en) * 2022-03-04 2024-09-12 AbbVie Deutschland GmbH & Co. KG Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancer
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
JP6018361B2 (ja) 2008-01-31 2016-11-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
CN106852149B (zh) * 2014-10-10 2021-08-27 依奈特制药公司 Cd73阻断
US10556959B2 (en) * 2014-11-07 2020-02-11 Xencor, Inc. Anti-CD39 antibodies and uses thereof
CA3005986A1 (en) * 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents
WO2017157948A1 (en) * 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
AU2018235092B2 (en) * 2017-03-16 2024-09-19 Innate Pharma Compositions and methods for treating cancer
WO2019178269A2 (en) * 2018-03-14 2019-09-19 Surface Oncology, Inc. Antibodies that bind cd39 and uses thereof

Also Published As

Publication number Publication date
AU2018368541B2 (en) 2025-06-12
WO2019096900A1 (en) 2019-05-23
IL273440A (en) 2020-05-31
CN111372606A (zh) 2020-07-03
EP3710052A1 (en) 2020-09-23
JP7383609B2 (ja) 2023-11-20
AU2018368541A1 (en) 2020-03-19
CN111372606B (zh) 2024-02-20
CA3075371A1 (en) 2019-05-23
KR102781619B1 (ko) 2025-03-14
BR112020009655A8 (pt) 2023-03-21
US20190218304A1 (en) 2019-07-18
KR20200088811A (ko) 2020-07-23
BR112020009655A2 (pt) 2020-10-13
JP2021502980A (ja) 2021-02-04

Similar Documents

Publication Publication Date Title
IL273440A (en) Strengthening the effect of ATP release
IL321844A (en) Menin–MLL interaction inhibitors
IL275482A (en) Asketamine for the treatment of depression
PL3512850T3 (pl) Inhibitory interakcji menina-mll
AU364417S (en) Back of the case
PL3177329T3 (pl) Układ do natychmiastowego uwalniania substancji aktywnych
IL263050B (en) History of Subtirum
GB201906004D0 (en) Synthesis of aei and cu-aei zeolites
IL274627A (en) Solid forms of valbenazine
PT3474822T (pt) Formulações de brincidofovir
IL265628A (en) Solid state forms of valbenazine
GB201522764D0 (en) Formulations of phosphate derivatives
SMT202200013T1 (it) Derivati di xantina sostituiti
IL269034A (en) Combination of isoindolinone derivatives with SGI-110
GB2562645B (en) Self-locking coupler
IL273949A (en) Drug derivatives of modified triazole derivatives and their uses
IL254666A0 (en) Crystalline forms of Aldecalcitol
GB201718277D0 (en) Modified solid polymethylaluminoxane
AP2017009770A0 (en) The game of gendaball
TWM534080U (en) Structural improvement of box body
PT3319956T (pt) Derivados de oxopiridina substituída
GB201417646D0 (en) Formulations of phosphate derivatives
IL234250A0 (en) Derivatives of n - melamine Melamine as a disinfectant and biocide